CHARLOTTESVILLE, Va., April 15, 2019 /PRNewswire/ -- Focused Ultrasound Foundation Chairman Neal F. Kassell, MD, was the keynote speaker at Analyst & Investor Day at the University Club in New York, NY, on April 11. The event was a first-of-its-kind gathering in the field of focused ultrasound and included key researchers, clinicians, financial analysts and institutional investors from around the world. The meeting was hosted by Profound Medical Corp., which provides a therapeutic platform combining real-time magnetic resonance imaging and ultrasound technology for the precise, incision-free ablation of diseased tissue.

Dr. Kassell spoke about the exponential growth of the focused ultrasound field, the technology's wide range of indications and mechanisms of action, and the global adoption of focused ultrasound as a therapeutic platform. Said Dr. Kassell, "This event was a milestone in the evolution of focused ultrasound, which validates that the field is transitioning from research to commercialization as we get closer to this revolutionary technology being widely available to millions of people worldwide who suffer from a variety of diseases. I was honored to be part of this group of forward-thinkers who share our goal of transforming treatment, improving outcomes and decreasing cost of care – in the shortest time possible – with this disruptive technology."

A full webcast archive is available at: https://www.webcaster4.com/Webcast/Page/2039/29965.
(requires free registration)

The meeting agenda is available here: https://profoundmedical.com/analystmeeting2019/#agenda.

About Focused Ultrasound
Focused ultrasound uses ultrasound energy guided by real-time imaging to treat tissue deep in the body without incisions or radiation. Where each individual beam passes through tissue, there is no effect. But, at the focal point, the convergence of the multiple beams of focused ultrasound energy results in many important biological effects, creating the possibility of treating a variety of medical disorders. Focused ultrasound is approved in the United States to treat essential tremor, Parkinson's, uterine fibroids, pain from bone metastases, and the prostate. The technology is in various stages of research and development for more than 100 diseases.

About the Focused Ultrasound Foundation
The Focused Ultrasound Foundation was created to accelerate the development of focused ultrasound, an early-stage noninvasive therapeutic technology with the potential to transform the treatment of many medical disorders. The Foundation is dedicated to ensuring that focused ultrasound becomes a mainstream therapy within years, not decades, and works to fund research, foster collaboration and build awareness among patients and professionals. Since its establishment in 2006, it has become the largest nongovernmental source of funding for focused ultrasound research. www.fusfoundation.org

About Profound Medical Corp.
Profound Medical (TXS:PRN) markets customizable therapies for incision- and radiation-free ablation of diseased tissue. Profound is commercializing TULSA-PRO®, which combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop thermal feedback control. Profound has completed enrollment in a multicenter, prospective clinical trial, which, if successful, is expected to support its application for approval to market in the United States. Profound also markets Sonalleve®, a therapeutic platform that has multiple regulatory approvals across several indications around the globe.

SOURCE Focused Ultrasound Foundation